MG
JSPR icon

Marex Group’s Jasper Therapeutics JSPR Stock Holding History

Marex Group’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,300
Closed -$73.8K – 933
2025
Q2 		$73.8K Sell
13,300
-39
-0.3% -$192 ﹤0.01% 578
2025
Q1 		$57.4K Buy
+13,339
New +$88.8K ﹤0.01% 634

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Marex Group's JSPR Position: Q3 2025 in Review

Marex Group sold out of Jasper Therapeutics (JSPR) in Q3 2025, closing a stake of 13,300 shares — an estimated $73.8K sold.

Marex Group first reported a position in JSPR in Q1 2025 and held it in 2 quarters. The position peaked at $73.8K in Q2 2025. 60 funds tracked by Wall St. Rank hold JSPR as of Q3 2025.

  • Marex Group reported no remaining Jasper Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Marex Group sold 13,300 Jasper Therapeutics shares in Q3 2025, an estimated $73.8K.
  • Marex Group first reported a position in Jasper Therapeutics in Q1 2025 and held it in 2 quarters.
  • Marex Group's Jasper Therapeutics position peaked at $73.8K in Q2 2025.
  • 60 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2025.

Based on Marex Group's 13F filing for Q3 2025, filed 14 Nov 2025.